The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time ...

The 15 drugs selected for negotiation include Eli Lilly’s breast-cancer drug Verzenio.

About 1.8 million people used one or more of the 15 drugs through Medicare Part D or Part B between November 2024 and October 2025, the CMS said. The batch of 15 meds accounted for about $27 billion ...

Lower prices from the third round of talks among Medicare and manufacturers will be announced in the fall but won’t go into ...

Tuesday's announcement is part of the Trump administration's efforts to reduce prescription drug costs for Americans, with ...

CMS's third drug negotiation cycle under the IRA targets high-expenditure drugs, impacting Medicare Part B and D spending. The list includes drugs for cancer, HIV, and diabetes, with significant ...

All 16 drug companies that inked deals with the Trump administration over the past few months still raised some of their ...

Every January, pharmaceutical companies increase the prices of hundreds of drugs. This year there's a disconnect between the ...